Chinese approval boosts Revlimid's long-term prospects
This article was originally published in Scrip
Celgene's Revlimid (lenalidomide) has been approved in China for multiple myeloma, opening up a growing new market that some analysts expect to make a meaningful contribution to the thalidomide derivative's global sales over the longer term.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.